Dipon Das, Ranjan Preet, Purusottam Mohapatra, Shakti Ranjan Satapathy, Chanakya Nath Kundu, Cancer Biology Division, KIIT School of Biotechnology, KIIT University, Bhubaneswar, Odisha 751024, India.
World J Gastroenterol. 2013 Nov 14;19(42):7374-88. doi: 10.3748/wjg.v19.i42.7374.
AIM: To study the mechanism of 5-fluorouracil (5-FU) resistance in colon cancer cells and to develop strategies for overcoming such resistance by combination treatment. METHODS: We established and characterized a 5-FU resistance (5-FU-R) cell line derived from continuous exposure (25 μmol/L) to 5-FU for 20 wk in 5-FU sensitive HCT-116 cells. The proliferation and expression of different representative apoptosis and anti-apoptosis markers in 5-FU sensitive and 5-FU resistance cells were measured by the MTT assay and by Western blotting, respectively, after treatment with Resveratrol (Res) and/or 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU). Apoptosis and cell cycle arrest was measured by 4',6'-diamidino-2-phenylindole hydrochloride staining and fluorescence-activated cell sorting analysis, respectively. The extent of DNA damage was measured by the Comet assay. We measured the visible changes in the DNA damage/repair cascade by Western blotting. RESULTS: The widely used chemotherapeutic agents BCNU and Res decreased the growth of 5-FU sensitive HCT-116 cells in a dose dependent manner. Combined application of BCNU and Res caused more apoptosis in 5-FU sensitive cells in comparison to individual treatment. In addition, the combined application of BCNU and Res caused a significant decrease of major DNA base excision repair components in 5-FU sensitive cells. We established a 5-FU resistance cell line (5-FU-R) from 5-FU-sensitive HCT-116 (mismatch repair deficient) cells that was not resistant to other chemotherapeutic agents (e.g., BCNU, Res) except 5-FU. The 5-FU resistance of 5-FU-R cells was assessed by exposure to increasing concentrations of 5-FU followed by the MTT assay. There was no significant cell death noted in 5-FU-R cells in comparison to 5-FU sensitive cells after 5-FU treatment. This resistant cell line overexpressed anti-apoptotic [e.g., AKT, nuclear factor κB, FLICE-like inhibitory protein), DNA repair (e.g., DNA polymerase beta (POL-β), DNA polymerase eta (POLH), protein Flap endonuclease 1 (FEN1), DNA damage-binding protein 2 (DDB2)] and 5-FU-resistance proteins (thymidylate synthase) but under expressed pro-apoptotic proteins (e.g., DAB2, CK1) in comparison to the parental cells. Increased genotoxicity and apoptosis were observed in resistant cells after combined application of BCNU and Res in comparison to untreated or parental cells. BCNU increased the sensitivity to Res of 5-FU resistant cells compared with parental cells. Fifty percent cell death were noted in parental cells when 18 μmol/L of Res was associated with fixed concentration (20 μmol/L) of BCNU, but a much lower concentration of Res (8 μmol/L) was needed to achieve the same effect in 5-FU resistant cells. Interestingly, increased levels of adenomatous polyposis coli and decreased levels POL-β, POLH, FEN1 and DDB2 were noted after the same combined treatment in resistant cells. CONCLUSION: BCNU combined with Res exerts a synergistic effect that may prove useful for the treatment of colon cancer and to overcome drug resistance.
目的:研究结肠癌 5-氟尿嘧啶(5-FU)耐药的机制,并通过联合治疗开发克服这种耐药性的策略。
方法:我们建立并鉴定了一个源自对持续暴露于 5-FU(25 μmol/L)20 周的 5-FU 敏感 HCT-116 细胞的 5-FU 耐药(5-FU-R)细胞系。通过 MTT 测定分别检测不同代表性凋亡和抗凋亡标志物在 5-FU 敏感和耐药细胞中的表达,Resveratrol(Res)和/或 1,3-双(2-氯乙基)-1-亚硝脲(BCNU)处理后通过 Western blotting 进行测量。通过 4',6'-二脒基-2-苯基吲哚盐酸盐染色和荧光激活细胞分选分析分别测量细胞凋亡和细胞周期停滞。通过彗星试验测量 DNA 损伤的程度。我们通过 Western blotting 测量 DNA 损伤/修复级联的可见变化。
结果:广泛使用的化疗药物 BCNU 和 Res 以剂量依赖性方式降低了 5-FU 敏感 HCT-116 细胞的生长。与单独治疗相比,BCNU 和 Res 的联合应用导致 5-FU 敏感细胞中的凋亡增加。此外,联合应用 BCNU 和 Res 导致 5-FU 敏感细胞中主要 DNA 碱基切除修复成分的显著减少。我们从 5-FU 敏感的 HCT-116(错配修复缺陷)细胞中建立了一个 5-FU 耐药细胞系(5-FU-R),除了 5-FU 之外,它对其他化疗药物(例如 BCNU、Res)没有耐药性。通过 MTT 测定评估 5-FU-R 细胞的 5-FU 耐药性。与 5-FU 敏感细胞相比,5-FU 处理后 5-FU-R 细胞中没有明显的细胞死亡。与亲本细胞相比,该耐药细胞系过度表达抗凋亡[例如 AKT、核因子 κB、FLICE 样抑制蛋白)、DNA 修复(例如,DNA 聚合酶 β(POL-β)、DNA 聚合酶 eta(POLH)、蛋白 Flap 内切核酸酶 1(FEN1)、DNA 损伤结合蛋白 2(DDB2)]和 5-FU 耐药蛋白(胸苷酸合成酶),但表达下调促凋亡蛋白(例如 DAB2、CK1)。与未处理或亲本细胞相比,耐药细胞在联合应用 BCNU 和 Res 后观察到更高的遗传毒性和凋亡。与亲本细胞相比,当将固定浓度(20 μmol/L)的 BCNU 与 18 μmol/L 的 Res 联合使用时,在亲本细胞中观察到 50%的细胞死亡,但在耐药细胞中需要低得多的 Res(8 μmol/L)浓度才能达到相同的效果。有趣的是,在耐药细胞中,在用相同的联合治疗后,观察到腺瘤性息肉病基因和降低的 POL-β、POLH、FEN1 和 DDB2 水平。
结论:BCNU 联合 Res 具有协同作用,可能对结肠癌的治疗和克服耐药性有用。
Cancer Chemother Pharmacol. 2015-9
Cancer Chemother Pharmacol. 2015-9
BMC Genom Data. 2022-7-6
World J Clin Cases. 2020-6-26
Chin Med J (Engl). 2011-6
Cancer Biol Ther. 2011-8-1
Chin J Cancer. 2011-7